Chandra Bhagat Pharma has allotted 66 lakh convertible warrants at Rs 44 per share, securing Rs 7.26 crore in upfront subscription funds. The move involves nine allottees, including promoter group members, and offers a conversion window of 18 months. This capital infusion bolsters the company's liquidity while signaling potential future equity dilution for shareholders.
Chandra Bhagat Pharma Secures Rs 7.26 Crore via Warrant Allotment
Chandra Bhagat Pharma Ltd has successfully allotted 66,00,000 convertible warrants at an issue price of Rs 44 each.
This transaction has resulted in an upfront cash inflow of Rs 7.26 crore for the company.
Reader Takeaway: The capital injection strengthens liquidity, though shareholders should watch for future equity dilution upon warrant conversion.
What just happened
The board of directors finalized the allotment of 66 lakh convertible warrants on a preferential basis following the receipt of in-principle approval from the BSE on October 12, 2026. The company collected 25% of the total issue price upfront, amounting to Rs 7.26 crore, in compliance with SEBI ICDR regulations. This issuance was previously sanctioned by shareholders during the Annual General Meeting held on September 1, 2026.
Why this matters
The funds raised will assist in strengthening the company's financial position. Each warrant carries the right to be converted into one fully paid-up equity share of Rs 10 face value within the next 18 months. For investors, this indicates a clear path for future capital expansion but also points to a potential increase in the company's total outstanding share count should the holders exercise their conversion rights.
Allottee Breakdown
The issuance is distributed among nine recipients:
- Promoter Group: Members including Hemant Chandravadan Bhagat, Chitra Hemant Bhagat, Pranav Hemant Bhagat, Prachi Pranav Bhagat, Mahesh C Bhagat, Jay Hemant Bhagat, and Lopa Mahesh Bhagat received a combined total of 50 lakh warrants.
- Non-Promoter: Samir Ramakant Dave and Chintan Vijay Makhecha were allotted 8 lakh warrants each.
What to track next
Investors should monitor the company's regulatory filings over the next 18 months. The primary point of interest remains the conversion status of these warrants. If holders do not exercise their right to convert within the 18-month tenure, the warrants will lapse, and the upfront money will be forfeited by the allottees to the company.